LUND, Sweden, June 11, 2014 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data related to the drug candidate paquinimod (57-57) for the treatment of systemic sclerosis, at the scientific conference "EULAR Annual European Congress of Rheumatology" held in Paris on June 11-14, 2014.
Active Biotech presentations include:
- (FRI0496) An open-label study to evaluate biomarkers and safety in systemic sclerosis (SSc) patients treated with paquinimod (ABR-215757). Hesselstrand R., Distler J.H., Riemekasten G., Törngren M., Nyhlén H. C., Stenström M., Andersson F., Eriksson H., Sparre B., Tuvesson H., Distler O. In this study, nine patients were treated with paquinimod 3 mg/day for eight weeks. The primary endpoint of the study was changes in disease related biomarkers. Paquinimod was well tolerated and effects on biomarkers relevant for SSc were observed during treatment.
- (FRI0516) Paquinimod (ABR-215757), an immunomodulatory compound, reduces fibrosis in the tight-skin 1 (TSK-1) model for systemic sclerosis. Stenström M., Nyhlén H. C., Nilsson M., Eriksson H., Törngren M., Distler J.H., Distler O., Sparre B., Tuvesson H. The purpose of this pre-clinical study was to investigate the effects of paquinimod in an experimental disease model for systemic sclerosis. The results show that paquinimod reduces development of skin fibrosis in this disease model.
For more detailed information, please see www.eular.org.
Paquinimod is a quinoline compound primarily intended for the treatment of systemic sclerosis. This rare disease is classified as an orphan drug indication. In 2011 and 2014, paquinimod was granted orphan medicinal product status in Europe and US for the indication systemic sclerosis. The Orphan Medicinal Product Designation is implemented to promote the development of drugs that may provide significant benefit to patients suffering from rare diseases identified as life-threatening or chronically debilitating.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is laquinimod (NERVENTRA®), an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis. Also tasquinimod for the treatment of prostate cancer, with a unique mode of action, is in pivotal phase. In addition, laquinimod has concluded Phase II development for Crohn's and Lupus. The company has two additional projects in clinical development, ANYARA primarily for the treatment of renal cell cancer and the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information.
For further information, please contact:
Tomas Leanderson, President & CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on June 11, 2014.
Active Biotech presents data on paquinimod at EULAR 2014 http://hugin.info/1002/R/1791728/616457.pdf